ARTICLE | Company News
Orion, Pharmacia deal
September 4, 2001 7:00 AM UTC
The companies will develop in the U.S. Orion's deramciclane 5-HT 2A and 2C receptor antagonist, which is in European Phase III testing to treat generalized anxiety disorder. Orion will fund U.S. Phase...